等待开盘 03-27 09:30:00 美东时间
+0.120
+0.42%
Xenon Pharmaceuticals shares surge after Phase 3 data show strong seizure reduction for azetukalner, with FDA filing planned for 2026.
03-09 21:26
美股周三早盘,专注于中枢神经系统(CNS)疾病创新疗法研发的生物制药公司Rapport Therapeutics(RAPP)股价重挫18.8%,此前该公司以每股26美元的价格完成2.5亿美元的公开发行。 此次发行预计将于2025年9月11日完成,所筹资金将用于支持公司的增长计划。 海量资讯、精准解读,尽在新浪财经APP 责任编辑:张俊 SF065
2025-09-10 22:54
The Phase 2a trial of Rapport Therapeutics' RAP-219 for refractory focal epilepsy is fully enrolled, with topline results expected in September 2025. The company highlighted the drug's potential in epilepsy, bipolar mania, and neuropathic pain during its investor day and has sufficient funds through 2026.
2025-06-02 18:45
Rapport Therapeutics announced that its management will participate in two upcoming investor conferences: the Jefferies Global Healthcare Conference in New York City on June 4 and the Goldman Sachs Global Healthcare Conference in Miami on June 9.
2025-05-27 11:00
Shares of The Gap, Inc. (NYSE:GAP) rose sharply in today's pre-market trading a...
2025-03-07 20:19